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Plasma 25-Hydroxyvitamin D and Risk of
Non-Melanoma and Melanoma Skin Cancer: A
Prospective Cohort Study
Shoaib Afzal1, Brge G. Nordestgaard1,2,3 and Stig E. Bojesen1,2,3
Sun exposure is a major risk factor for skin cancer and is also an important source of vitamin D. We tested the
hypothesis that elevated plasma 25-hydroxyvitamin D (25-OH-vitD) associates with increased risk of non-
melanoma and melanoma skin cancer in the general population. We measured plasma 25-OH-vitD in 10,060
white individuals from the Danish general population. During 28 years of follow-up, 590 individuals developed
non-melanoma skin cancer and 78 developed melanoma skin cancer. Increasing 25-OH-vitD levels, by clinical
categories or by seasonally adjusted tertiles, were associated with increasing cumulative incidence of non-
melanoma skin cancer (trend P¼ 2 10 15 and P¼ 3 10 17) and melanoma skin cancer (P¼ 0.003 and
P¼ 0.001). Multivariable adjusted hazard ratios of non-melanoma skin cancer were 5.04 (95% confidence interval
(CI): 2.78–9.16) for 25-OH-vitD X50 vs. o25nmol l 1, and 4.02 (2.45–6.60) for top versus bottom tertile.
Multivariable adjusted hazard ratios of melanoma skin cancer were 4.7 (0.96–23.3) for 25-OH-vitD X50 vs.
o25nmol l 1, and 6.3 (1.38–28.8) for top versus bottom tertile. The absolute 20-year risk was 11% for non-
melanoma skin cancer and 1.5% for melanoma skin cancer, in participants with age 460 years, 25-OH-vitD
winter levels X50nmol l 1, and performing outdoor exercise. In conclusion, we show that increasing levels of
25-OH-vitD are associated with increased risk of non-melanoma and melanoma skin cancer.
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INTRODUCTION
UV radiation from sun exposure is a main environmental risk
factor for non-melanoma and melanoma skin cancer
(Armstrong and Kricker, 1993, 2001; Kricker et al., 1995;
Gallagher et al., 1995a, b). However, the wavelength of UV
radiation that causes DNA damage in skin cells also induces
vitamin D production in keratinocytes (Holick et al., 1977,
1979; Adams et al., 1982; MacLaughlin et al., 1982; Freeman
et al., 1989), which promotes differentiation and reduces
proliferation in normal skin cells and skin cancer cell lines
(Colston et al., 1981; Eisman et al., 1987; Evans et al., 1996;
Bikle, 2004; Tang et al., 2011b). Furthermore, vitamin D
receptor knockout mice have increased susceptibility toward
UV radiation–induced skin tumors (Zinser et al., 2002).
Thus, an increase in vitamin D levels, measured by plasma
25-hydroxyvitamin D (25-OH-vitD), might reduce the risk of
non-melanoma and melanoma skin cancer due to the afore-
mentioned effects of vitamin D (Tang et al., 2010; Newton-
Bishop et al., 2011). In contrast, if plasma 25-OH-vitD
is a surrogate marker for sun exposure then higher levels
may be associated with increased rather than decreased risk of
non-melanoma and melanoma skin cancer (Asgari et al.,
2010).
We tested the hypothesis that elevated plasma 25-OH-vitD
levels associate with increased risk of non-melanoma and
melanoma skin cancer in the general population. For this
purpose, we studied 10,060 white individuals from the
Copenhagen City Heart Study followed up for up to 28 years.
Two aspects make this cohort unique: in Northern Europe,
UV-B radiation from the sun is only adequate for sufficient
endogenous vitamin D production in the skin during the
summer months from May to September, and food has never
been fortified with vitamin D in Denmark. Thus, this cohort
from the Danish general population allows the determination
of the natural history of the association of vitamin D levels
with risk of non-melanoma and melanoma skin cancer.
However, our data do not account for sun exposure and
sunburns during holidays in Denmark or abroad.
RESULTS
The seasonal variation in plasma 25-OH-vitD is depicted in
Figure 1, with the highest levels in September and the lowest
levels in February. Furthermore, we remeasured plasma
25-OH-vitD levels in 400 healthy participants of the 10,060
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participants B10 and 20 years after the initial measurements:
the relationship between baseline, second, and third measure-
ment is illustrated in Figure 2, showing the levels of plasma
25-OH-vitD adjusted for season, age, and body mass index
(BMI). There is a narrowing of the range of values in the
follow-up measurements, i.e., there is evidence of regression
toward the mean. However, the ranking derived from baseline
measurements remains throughout the follow-up period,
indicating a stable level over longer time periods up to 20
years. Measurements from the 1981–1983 examination corre-
lated with the measurements from the 1991–1994 (Spearman’s
r¼0.41, P¼ 10 17) and 2001–2003 examinations (Spear-
man’s r¼0.40, P¼1016).
Increasing levels of plasma 25-OH-vitD were associated
with decreasing age, decreasing cumulative tobacco con-
sumption, decreasing BMI, increasing income, increased
intensity of leisure-time activity, and with regular cycling or
running (Table 1). Median plasma 25-OH-vitD was
41 nmol l1 for the whole population, 48 nmol l1 among
those who later developed non-melanoma skin cancer, and
51 nmol l1 among those who later developed melanoma skin
cancer. A total of 590 participants developed non-melanoma
skin cancer and 78 participants developed melanoma during
up to 28 years of follow-up. Table 1 also shows whether
covariates selected a priori associate with the risk of skin
cancer.
Cumulative incidence
Cumulative incidence of non-melanoma and melanoma skin
cancer increased stepwise with increasing levels of plasma 25-
OH-vitD, expressed in clinical categories (trend: P¼ 21015
and P¼0.003) and in seasonally adjusted percentile categories
(P¼310 17 and P¼ 0.001) (Figure 3).
Relative risk
Adjusted hazard ratios for non-melanoma and melanoma skin
cancer increased with increasing levels of plasma 25-OH-
vitD, by clinical categories and by seasonally adjusted tertiles,
in both of our models (Figure 4). Multivariable adjusted hazard
ratios for non-melanoma skin cancer were 5.04 (95% CI:
2.78–9.16) for 25-OH-vitD X50 vs. o25 nmol l 1, and 4.02
(2.45–6.60) for 467th vs. p34th percentile. Multivariable
adjusted hazard ratios for melanoma were 4.72 (0.96–23.3)
for plasma 25-OH-vitD X50 vs. o25 nmol l1, and 6.31
(1.38–28.8) for 467th vs. p34th percentile.
Analyzing 25-OH-vitD as a continuous variable showed a
multivariable adjusted hazard ratio of 1.23 (1.14–1.32) for
non-melanoma skin cancer and 1.45 (1.22–1.73) for mela-
noma skin cancer per 10 nmol l 1 increase in plasma 25-OH-
vitD. Similarly, the multivariable adjusted hazard ratio for a
10% increase in seasonally adjusted percentile of plasma 25-
OH-vitD was 1.23 (1.15–1.32) for non-melanoma skin cancer
and 1.27 (1.05–1.53) for melanoma.
Interaction analyses did not show any significant interac-
tions between 25-OH-vitD, as a continuous variable, and any
of the covariates on risk of non-melanoma skin cancer or
melanoma.
Relative risk: subgroup analyses
In separate analyses, the association of very high levels of
plasma 25-OH-vitD with non-melanoma skin cancer and
melanoma were carried out. The multivariable adjusted
hazard ratios for non-melanoma skin cancer was 5.28 (95%
CI: 1.66–16.8) for 25-OH-vitD X100 vs. o25 nmol l 1. The
corresponding multivariable adjusted hazard ratios for mela-
noma was 9.58 (2.37–38.7).
As melanoma developing in sites often exposed to UV
radiation may be different from melanomas in sun-unexposed
sites, additional analyses for melanoma risk in sun-exposed
sites (head and extremities, 40 cases) versus relatively unex-
posed sites (trunk and other sites, 38 cases) were carried out.
The multivariable adjusted hazard ratio was 1.58 (1.25–2.00)
for melanoma in sun-exposed sites per 10 nmol l1 increase in
plasma 25-OH-vitD, whereas it was 1.24 (0.93–1.66) for
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Figure 1. Seasonal variation in 25-hydroxyvitamin D. Seasonal variation in
25-hydroxyvitamin D levels according to calendar month of blood sampling
(based on 10,060 individuals from the Danish general population, the
Copenhagen City Heart Study). Apr, April; Aug, August; Dec, December; Feb,
February; Jan, January; Mar, March; Nov, November; Oct, October; Sept,
September.
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Figure 2. Repeated measurements of plasma 25-hydroxyvitamin D (P-25-OH-
vitD) 10 and 20 years apart. Median adjusted P-25-OH-vitD levels according
to baseline tertiles constructed on the basis of measurements in the 1981–1983
examination. Repeated measurements of P-25-OH-vitD were 10 and 20 years
apart on the same individuals. P-25-OH-vitD was adjusted for age, body mass
index, and month of blood sampling. Solid circles are median levels and
the associated whiskers are 95% confidence intervals (based on 400 of the
10,060 individuals from the Danish general population, the Copenhagen City
Heart Study).
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relatively unexposed sites. The corresponding hazard ratios for
a 10% increase in seasonally adjusted percentile were 1.31
(1.00–1.71) and 1.19 (0.90–1.57), respectively.
Absolute risk
Absolute 20-year risk of non-melanoma and melanoma skin
cancer increased with increasing plasma 25-OH-vitD across
age groups and irrespective of whether the blood samples
were collected in winter (November–April) or summer
(May–October) (Figure 5). The highest absolute 20-year risk
of non-melanoma skin cancer of 11% was found in partici-
pants aged 460 years with 25-OH-vitD levels X50 nmol l 1
in winter months, who regularly performed outdoor exercise.
The highest absolute 20-year risk of melanoma of 1.5% was
found in participants aged440 years with 25-OH-vitD levels
X50 nmol l1 in winter months, who regularly performed
outdoor exercise. Gender was not associated with difference
in absolute risk of either of the cancers.
Table 1. Baseline characteristics according to clinical categories for 25-hydroxyvitamin D plasma levels
Plasma 25-hydroxyvitamin D (nmol l 1) Non-melanoma skin cancer Melanoma
o25
(n¼2,362)
25–49.9
(n¼ 4,035)
450
(n¼3,663) P-value1 HR (95% CI) P-value2 HR (95% CI) P-value2
Men, no. (%) 1,074 (45) 1,760 (44) 1,575 (43) 0.07 1.26 (1.07–1.49) 0.007 1.47 (0.94–2.30) 0.09
Age, years o0.001 o0.001 0.13
Median 59 59 57
Interquartile range 50–65 49–65 48–65
Cumulative tobacco consumption, pack-years o0.001 1.00 (0.99–1.00) 0.84 0.99 (0.98–1.01) 0.82
Median 24 19 18
Interquartile range 10–38 5–33 3–31
Body mass index, kgm2 o0.001 0.98 (0.96–1.00) 0.04 0.98 (0.93–1.04) 0.60
Median 25 25 24
Interquartile range 23–29 23–28 22–27
Income group, no. (%)3 o0.001 o0.001 0.55
Low (o84,000 DKr) 927 (40) 1,262 (32) 974 (27) 1 1
Medium (84,000–
192,000 DKr)
1,031 (44) 1,874 (47) 1,714 (47) 1.15 (0.93–1.43) 1.43 (0.77–2.66)
High (4192,000 DKr) 368 (16) 844 (21) 941 (26) 1.57 (1.23–2.00) 1.28 (0.62–2.65)
Occupational physical exertion, no. (%) 0.074 0.064 0.354
Low 798 (34) 1,363 (34) 1,273 (35) 1 1
Occasional 864 (37) 1,596 (40) 1,480 (40) 0.76 (0.63–0.92) 1.06 (0.61–1.84)
Moderate 510 (22) 858 (21) 752 (21) 0.88 (0.70–1.10) 1.36 (0.75–2.50)
High 108 (5) 141 (3) 111 (3) 0.68 (0.40–1.16) 1.23 (0.36-4.15)
Without work 82 (3) 77 (2) 47 (1) — —
Leisure-time activities, hours per week2 o0.001 0.08 0.03
p2 598 (25) 686 (17) 410 (11) 1 1
2–4 (light activity) 1,115 (47) 1,986 (49) 1,792 (49) 1.14 (0.88–1.47) 0.89 (0.43–1.81)
2–4 (heavy activity) or
X4 (light activity)
622 (26) 1,282 (32) 1,346 (37) 1.25 (0.96–1.63) 1.61 (0.96–1.63)
X4 (heavy activity) 27 (1) 79 (2) 115 (3) 1.36 (0.75–2.46) 1.87 (0.50–7.03)
Regular cycling or running o0.001 o0.001 0.02
No 1,545 (65) 2,274 (56) 1,774 (48) 1 1
Yes 817 (35) 1,761 (44) 1,889 (52) 1.36 (1.15–1.61) 1.75 (1.10–2.80)
Abbreviations: CI, confidence interval; HR, hazard ratio.
1P-values were calculated using Cuzick’s non-parametric trend test.
2Trend test or use of continuous variable, Cox regression.
31981–1983 income levels (1 US$ B6 DKr).
4Excluding participants not working. The following covariates had missing values: income group: 125 observations, leisure-time activities: 2 observations, and
body mass index: 18 observations.
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DISCUSSION
We found that increasing levels of plasma 25-OH-vitD were
associated with increased risk of non-melanoma skin cancer
and melanoma in this prospective study of 10,060 participants
from the general population followed up for up to 28 years.
Our data lend support to the hypothesis that plasma 25-OH-
vitD can be used as a surrogate marker for UV-B radiation
from sun exposure and hence be used to identify persons at
risk of acquiring skin cancer. Biologically, this is supported by
previous studies that have shown that UV radiation induces
both DNA damage and vitamin D synthesis (Holick et al.,
1977, 1979; Adams et al., 1982; MacLaughlin et al., 1982;
Freeman et al., 1989), that vitamin D formation in the skin
increases with increasing UV-B radiation exposure (Adams
et al., 1982; MacLaughlin et al., 1982), and that in areas with
high UV index the incidence of non-melanoma skin cancer
and, to a lesser degree, melanoma is increased in Caucasians
(Armstrong and Kricker, 2001), as are plasma 25-OH-vitD
levels (McCullough et al., 2010).
In support of our findings that elevated plasma 25-OH-vitD
may be used as a risk factor for non-melanoma skin cancer
and melanoma, a previous cohort study demonstrated that
elevated plasma 25-OH-vitD levels associate with increased
risk of non-melanoma skin cancer (Asgari et al., 2010).
However, other case–control and cohort studies have shown
an inverse relationship between plasma 25-OH-vitD and risk
of non-melanoma and melanoma skin cancer (Tang et al.,
2010; Newton-Bishop et al., 2011). Contrary to the latter
studies, a randomized study did not show the expected
decreased risk of non-melanoma and melanoma skin cancer
with vitamin D supplementation (Tang et al., 2011a), although
a post hoc analysis did show that supplementing with vitamin
D and calcium reduced the risk of melanoma in cases with a
history of non-melanoma skin cancer. However, the authors
themselves were not confident that this result was genuine.
Compared with previous studies on the association of plasma
25-OH-vitD and risk of non-melanoma and melanoma skin
cancer, our study has more cases of non-melanoma skin
cancer, although fewer cases of melanoma, a longer follow-
up, and a more complete case ascertainment due to the
Danish Cancer Registry.
A potential limitation is that our cohort consists of whites of
Danish descent living in Denmark (551–581 North) with less
sun exposure than closer to the equator; consequently, our
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Figure 3. Cumulative incidence of non-melanoma skin cancer and melanoma skin cancer by plasma 25-hydroxyvitamin D (P-25-OH-vitD). Cumulative
incidence of non-melanoma skin cancer and melanoma skin cancer by P-25-OH-vitD in clinical categories and in seasonally adjusted tertiles (expressed as
percentiles). The cumulative incidences were plotted using Fine and Gray competing risks regression accounting for the competing risk of death. Furthermore, the
analysis is adjusted for age and year of birth to account for calendar effects. P-values for trend indicate whether increasing levels of 25-OH-vitD are associated with
increasing cumulative incidence of non-melanoma skin cancer and melanoma (based on 10,060 individuals from the Danish general population, the Copenhagen
City Heart Study, followed for up to 28 years after blood sampling). CI, confidence interval.
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findings would be most relevant for individuals with a similar
level of sun exposure and for similar 25-OH-vitD levels.
Furthermore, skin phenotype or pigmentation was not
recorded. Similarly, sun exposure and sunburns during holi-
days in Denmark or abroad were not recorded, and as
sunburn is predictive of melanoma risk this represents another
limitation. A sun-exposure variable that takes into account
incidence of sunburn and sun exposure would have been
preferable, especially considering that one of our sun-expo-
sure variables, occupational physical exertion, was not asso-
ciated with vitamin D levels. The delay in measurement from
blood sampling in 1981–1983 to measurement in 2009–2010
could raise concern of potential decay of plasma 25-OH-vitD.
However, we observed the expected seasonal variation in
plasma 25-OH-vitD, that the median levels across plasma
samples with storage times of 10, 20, and 30 years were
similar, the median levels were comparable to similar popula-
tions (McCullough et al., 2010; Durup et al., 2012; Husemoen
et al., 2012), 25-OH-vitD measurements are very resistant
to preanalytical conditions and storage times of several
years (Lissner et al., 1981; Ocke et al., 1995; Antoniucci
et al., 2005), and a reduced quality of plasma 25-OH-vitD
measurements would tend to weaken associations rather than
inflate them. This potential limitation thus cannot explain our
positive results, and in fact the well-preserved seasonal
variation in plasma 25-OH-vitD with the highest levels in
September and the lowest levels in February suggest that
baseline 25-OH-vitD is a valid marker of sun exposure of the
individual. Despite the generally high coverage of the Danish
Cancer Registry (Storm, 1988, 1991; Storm et al., 1997),
we cannot exclude underreporting of non-melanoma skin
cancers, as they are difficult to register (owing to lack of
histological verification, treatment in private settings, etc), and
extra checks might have been needed to ensure that all non-
cases were free of non-melanoma skin cancer, which was not
done. However, the admixture of cases into the non-case
population would tend to weaken the association rather than
inflate it, and thus cannot explain our results.
The strengths of our study are the up to 28 years of complete
follow-up, a homogenous population, and high case ascer-
tainment. We used a random sample of the general popula-
tion, the Copenhagen City Heart Study, which makes our
results applicable to the general population. In addition, we
measured plasma 25-OH-vitD that reflects internal vitamin D
status, which is superior to evaluating dietary intake alone.
Moreover, the association of plasma 25-OH-vitD with risk of
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Figure 4. Hazard ratios for non-melanoma skin cancer and melanoma skin cancer by plasma 25-hydroxyvitamin D (P-25-OH-vitD). Hazard ratios for
non-melanoma skin cancer and melanoma skin cancer by P-25-OH-vitD in clinical categories and in seasonally adjusted tertiles (expressed as percentiles).
Multivariable models were adjusted for gender, pack-years, body mass index, income, occupational physical exertion, intensity of leisure-time activities, and
regular cycling or running. Furthermore, the models using the clinical categories for 25-OH-vitD were adjusted for month of blood sample. The analyses are
adjusted for age and year of birth to account for calendar effects. Risk estimates were corrected for regression dilution bias (based on 10,060 individuals from the
Danish general population, the Copenhagen City Heart Study, followed for up to 28 years after blood sampling).
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non-melanoma skin cancer and melanoma was robust irre-
spective of the method of seasonal adjustment and statistical
model, i.e., the association was present in relative risk and
absolute risk models, as well as in differently adjusted models.
Finally, because we measured 25-OH-vitD on 400 individuals
10 years apart, we were able to correct for regression dilution
bias, i.e., a correction that helps avoid underestimation of risk
estimates owing to imprecise measurement of 25-OH-vitD
(Clarke et al., 1999).
In Northern Europe, UV-B radiation from the sun is only
adequate for sufficient endogenous vitamin D production in
the skin during the summer months, and food has never been
fortified with vitamin D in Denmark. The present study
therefore allows for the determination of the natural history
of the association of vitamin D levels with risk of non-
melanoma and melanoma skin cancer. However, through
dietary consumption of vitamin D–rich products and through
the use of supplements, plasma 25-OH-vitD levels might
increase, most likely without increasing the risk of skin cancer.
As in recent years much more attention is being paid to
vitamin D, plasma levels measured in the early 1980s are
likely less influenced by such supplements than would be
currently the case. Thus, in populations deriving the majority
of their vitamin D from dietary sources, the present observed
association may be attenuated, either in the current cohort if
the participants changed their behavior as indicated during the
follow-up period or in more recent cohorts having been
collected after the focus on vitamin D supplementation has
increased.
Our study adds to the risk–benefit discussion regarding sun
exposure in two important ways: first, that plasma 25-OH-vitD
probably acts as a surrogate marker for sun exposure at the
population level and, second, that there is an increase in skin
cancer risk when going from the low range of 25-OH-vitD to
the high range, i.e., recommended sun exposure may be
enough to induce premalignant or malignant changes in the
skin. However, our study cannot, and is not designed to,
assess the risk–benefit profile of sun exposure or increased 25-
OH-vitD with regard to other health outcomes, which could
justify current recommendations regarding daily sun exposure.
Similarly, our study does not definitely disprove the hypothesis
that levels in the sufficient range of plasma 25-OH-vitD can
reduce the risk of developing skin cancer.
In conclusion, we have shown that increasing levels of
plasma 25-OH-vitD are associated with increased risk of non-
melanoma skin cancer and melanoma.
MATERIALS AND METHODS
Study design
The Copenhagen City Heart Study is a prospective cohort study of the
Danish general population initiated in 1976–1978 with follow-up
examinations in 1981–1983, 1991–1994, and 2001–2003 (Bojesen
et al., 2003; Nordestgaard et al., 2007). Individuals aged 20–100
years were drawn randomly from the national Danish Central Person
Register to reflect age and gender distribution in the whole population
and invited to participate; all inhabitants in Denmark are uniquely
identified through their central person registration number that also
holds information on date of birth and gender.
The present study included 10,060 participants from the 1981–
1983 examination: 17,312 were invited, 12,214 participated (71%),
and 10,060 (58%) had available plasma samples for 25-OH-vitD
measurement; 147 participants with a diagnosis of skin cancer before
study entry were excluded (see Cancer end points).
A Danish ethics committee approved the study (KF100.2039/91
and KF01-144/01). The Declaration of Helsinki Principles were
followed and all participants provided written informed consent.
Measurements of 25-OH-vitD
Plasma samples collected at baseline in 1981–1983 were stored at
 201C until 2009–2010 when 25-OH-vitD was measured using the
DiaSorin Liaison 25-OH-vitD TOTAL assay (Ersfeld et al., 2004).
Assay precision was tested daily, whereas assay accuracy was tested
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Figure 5. Absolute 20-year risk of non-melanoma skin cancer and melanoma skin cancer. Absolute 20-year risk of non-melanoma skin cancer and
melanoma skin cancer by 25-hydroxyvitamin D levels, age, season of blood sampling, and participation in regular outdoor exercise (running or cycling) calculated
by using the regression coefficients from a Poisson regression model. Apr, April; Nov, November; Oct, October.
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monthly using an external quality-control program. The inter-assay
coefficient of variance was 10% for low-level controls
(B40 nmol l 1) and 8% for high-level controls (B135 nmol l 1).
Covariates
Selection of covariates was based on review of literature on
determinants of skin cancer risk and levels of vitamin D (Rubin
et al., 2005; Asgari et al., 2009; McCullough et al., 2010; Pothiawala
et al., 2012). Variables suspected to possibly affect both skin cancer
risk and vitamin D levels were selected as covariates.
Information on smoking habits was obtained from self-reported
questionnaires completed together with an examiner on the day of
attendance. Daily tobacco consumption (grams per day) was calcu-
lated for current smokers. Cumulative tobacco consumption was
calculated for former and current smokers in pack-years; a pack-year
was defined as 20 g of tobacco per day for a year. BMI was calculated
as measured weight (kilograms) divided by measured height (meters)
squared. Participants were also asked about their level of income.
Information on occupational physical exertion, intensity of leisure-
time activities, and running and cycling habits were obtained from
self-reported questionnaires and used as surrogate markers for sun
exposure; i.e., all three variables were included in our analyses as
separate variables to capture sun exposure.
Cancer end points
Diagnoses of non-melanoma and melanoma skin cancer from 1943
to December 2008 were obtained from the Danish Cancer Registry
that identifies 98% of cancer cases in Denmark from all hospitals and
private practicing pathologists (Storm, 1988, 1991; Storm et al.,
1997). This is required by law. The diagnoses from date of blood
sampling and onward were classified according to the World Health
Organization international classification of diseases 10th edition
(ICD-10): non-melanoma skin cancer as C44 and melanoma as
C43. None of the non-melanoma skin cancer or melanoma
diagnoses were based on self-report, and all were from the Danish
Cancer Registry. Both cancer types were recorded from 1943. In
addition, from 1978 and onward histological subtypes of non-
melanoma skin cancer, i.e., basal cell carcinoma, spinocellular
carcinoma, and other rare histological types of non-melanoma skin
cancer, were all recorded.
Follow-up time for each subject began at the day of blood sampling
in 1981–1983 and ended at first skin cancer, death (n¼ 6,268),
emigration (n¼ 54), or December 2008, whichever occurred first.
The median follow-up time to first skin cancer, death, emigration, or
December 2008 was 20.5 years (range 0.04–28). Follow-up was
100% complete, i.e., we did not lose track of a single individual.
Statistical analyses
A priori we divided baseline plasma 25-OH-vitD into the following
clinical categories of450 nmol l 1 (sufficient levels), 25–50 nmol l 1
(insufficient levels), and o25 nmol l 1 (deficient levels). In addition,
because concentration of 25-OH-vitD was expected to vary according
to time of the year owing to the high-latitude geographical position of
Denmark, we also used seasonally adjusted 25-OH-vitD levels. Two
strategies were applied to adjust for the seasonal variation in vitamin
D. First, we used unadjusted 25-OH-vitD levels in regression
analyses while adjusting for calendar month of blood sampling. Thus,
25-OH-vitD was adjusted for calendar month of blood sampling when
using clinical categories in analyses. Second, calendar month–specific
cutoff points were obtained by assigning subjects to percentile
categories within the same month of sampling. We divided the
seasonally adjusted values into tertiles. For trend tests across ordered
groups, individuals were assigned the median value of their group,
either as absolute values or as percentiles.
Cumulative incidences were estimated using the competing risk
proportional subhazard models by the method of Fine and Gray (Fine
and Gray, 1999), in which competing risk of death was accounted
for. The analyses were adjusted for age and year of birth to account
for calendar effects. We used age as the time scale. The cumulative
incidence functions were plotted by seasonally unadjusted clinical
categories and seasonally adjusted percentile categories.
Cox proportional hazards regression was used to estimate hazard
ratios with 95% CI for incident cancer. We used age as the time scale
with delayed entry (left truncation). Thus, age differences were
automatically adjusted for and referred to in text, tables, and figures
as age adjusted. However, for the test of interaction of age with 25-
OH-vitD levels on cancer risk, we used years of follow-up as the time
scale, as using age as the time scale does not allow testing for
interactions with age. Furthermore, all analyses were adjusted for year
of birth, in addition to age, to account for calendar effects. Multi-
variable adjusted Cox regression models included gender, age,
cumulated tobacco consumption in pack-years, BMI, income, occu-
pational physical exertion, physical intensity of leisure-time activities,
running and cycling habits, and calendar month of blood draw.
Interactions were tested for using likelihood ratio tests with Cox
regression models including and excluding multiplicative two-factor
interaction terms. The proportional hazards assumption was tested for
in Cox regression models using Schoenfeld residuals; no departures
were detected for the different plasma 25-OH-vitD variables used.
Missing data were imputed using multivariable chained imputation
(STATA:mi impute chained), in which age and gender were indepen-
dent variables and BMI, physical intensity of leisure-time activities,
and income were dependent variables in the model. Hazard ratios
and CIs were corrected for regression dilution bias (Clarke et al.,
1999), using plasma 25-OH-vitD from 400 individuals without non-
melanoma skin cancer, melanoma skin cancer, other cancers, or
other chronic diseases participating in both the 1991–1994 and
2001–2003 examinations of the Copenhagen City Heart Study; this
correction helps to avoid underestimation of risk estimates, but does
not affect whether results are significant. The regression dilution ratio
was 3.1 on samples taken 10 years apart and 2.2 on samples taken
20 years apart; the latter was used to adjust risk estimates.
Estimated absolute risks for non-melanoma and melanoma skin
cancer were calculated by using the regression coefficients from a
Poisson regression model with the same covariates as the Cox
regression and, in addition, age at entry in three groups (p40 years,
440 to p60 years, and 460 years). We analyzed the data with the
statistical package STATA 11.2 (STATA, College Station, TX).
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